In patients with severe hemophilia A, standard treatment is regular prophylactic and episodic intravenous infusions of factor VIII. However, these treatments are burdensome, especially for children, and may lead to the formation of anti-factor VIII alloantibodies (factor VIII inhibitors). Emicizumab (ACE910), a humanized bispecific antibody mimicking the cofactor function of factor VIII, was developed to abate these problems.
H emophilia A is a serious bleeding disorder caused by a deficiency of clotting factor VIII. Approximately 50% of patients have severe hemophilia A, 1 defined as less than 1% residual factor VIII activity (<1 IU per deciliter). 2 Such patients have severe bleeding from early childhood, and without appropriate treatment, recurrent bleeding into joints can lead to irreversible hemoarthropathy. 3, 4 Standard treatment for hemophilia A includes regular prophylaxis and episodic treatment with recombinant or plasma-derived factor VIII. The goals of prophylaxis with factor VIII are to increase factor VIII activity to at least a moderate level (1 to 5 IU per deciliter) 5 and to reduce bleeding episodes and joint damage. 6 However, there are significant barriers to this treatment. The standard regimen, which consists of intravenous administration of factor VIII three times per week or every other day, 6, 7 can impose a substantial burden on patients, particularly children and patients with poor venous access. [8] [9] [10] [11] Furthermore, despite large improvements in hemostatic activity with regular prophylaxis, the primary aim of this treatment is to achieve factor VIII activity of at least 1 IU per deciliter at trough drug levels, yet the level of activity required to minimize the risk of joint bleeding is 10 to 15 IU per deciliter. 12 Moreover, induction of anti-factor VIII alloantibodies (factor VIII inhibitors), which occurs in 30% of patients with severe hemophilia A, renders treatment with factor VIII ineffective. 13 The main treatment for patients in whom factor VIII inhibitors develop is episodic treatment or regular prophylaxis with bypassing agents, including recombinant activated factor VII (factor VIIa) or activated prothrombin complex concentrates, which provide imperfect control of bleeding. 14, 15 Another option is induction of immune tolerance, an approach that aims to eradicate factor VIII inhibitors. Immune tolerance induction is successful in approximately 70% of patients, 16 but it is intensive, requiring frequent and long-term administration of factor concentrate, [17] [18] [19] and many patients with a high factor VIII inhibitor titer are not eligible for this treatment. 19 A more effective, less burdensome treatment is needed for patients with hemophilia A. Emicizumab (ACE910), developed to help meet this need, is a humanized bispecific antibody that binds to and bridges activated factor IX (factor IXa) and factor X, thereby acting as a factor VIIImimetic agent (see Fig. S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). 20, 21 Because of its unique structure, emicizumab is not expected to induce or be affected by factor VIII inhibitors. It has good subcutaneous bioavailability in nonhuman primates and a long half-life (4 to 5 weeks) in healthy volunteers. 22, 23 Emicizumab has been shown to have in vivo hemostatic activity in a nonhuman primate model of acquired hemophilia A 22,24 ; it also has been shown to have limited adverse effects in healthy volunteers after a single subcutaneous administration of 1 mg or less per kilogram of body weight. 23 In this study, we evaluated the safety, pharmacokinetics, and pharmacodynamics of weekly subcutaneous administration of emicizumab in patients who had severe hemophilia A with or without factor VIII inhibitors. We also performed an exploratory analysis to determine whether emicizumab can prevent bleeding and maintain acceptable hemostatic activity. 25 
Me thods

Study Oversight
This was a 12-week, open-label, nonrandomized, interindividual dose-escalation study involving Japanese patients with severe hemophilia A at six hemophilia treatment centers in Japan. The study was conducted from May 2013 through August 2014 in accordance with the International Conference on Harmonisation Guidelines for Good Clinical Practice; it was approved by the institutional review board at each participating center and was registered before initiation. All patients gave written informed consent before enrollment. The protocol, which was developed by the sponsor, Chugai Pharmaceutical, is available at NEJM.org.
The first author, along with three authors employed by the sponsor, designed the study. Two authors employed by the sponsor analyzed the data and vouch for the accuracy and completeness of the data and for the adherence of the study to the protocol. The sponsor had the n engl j med 374;21 nejm.org May 26, 2016
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T h e ne w e ngl a nd jou r na l o f m e dicine right to review the manuscript, and all authors had access to the data and made the decision to submit the manuscript for publication. The first author and one author employed by the sponsor prepared the first draft with writing assistance provided by an employee of the sponsor; assistance with subsequent drafts was provided by ProScribe, part of Envision Pharma Group, under contract with Chugai Pharmaceutical.
Study Patients and Study Design
Japanese patients (12 to 59 years of age) who had severe hemophilia A, with or without factor VIII inhibitors, were eligible for enrollment in the study. Before enrollment, patients without factor VIII inhibitors had received regular prophylaxis with factor VIII; patients with factor VIII inhibitors had received episodic therapy or regular prophylaxis with a bypassing agent and had had a total of six or more bleeding episodes in the previous 6 months. Major exclusion criteria were a history of a bleeding disorder other than congenital hemophilia A; clinically significant infection other than infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus; and a value for protein C activity, free protein S antigen level, or antithrombin activity that was below the low end of the normal range at screening. At least two patients with and two patients without factor VIII inhibitors were enrolled in each cohort.
Enrolled patients were assigned to cohort 1, cohort 2, or cohort 3 and received subcutaneous emicizumab (80 mg per milliliter) at an initial dose of 1.0 mg per kilogram of body weight (cohort 1) or 3.0 mg per kilogram (cohorts 2 and 3) at week 0 (day 1), followed by a onceweekly subcutaneous dose of 0.3, 1.0, or 3.0 mg per kilogram (cohorts 1, 2, and 3, respectively) from week 1 through week 12. The initial and subsequent doses for cohort 3 were the same. On the basis of pharmacokinetic data modeling from a previous nonclinical study, 22 these doses were predicted to result in plasma emicizumab concentrations at 1 week after each administration (trough levels) of 11.2 μg per milliliter (cohort 1), 37.3 μg per milliliter (cohort 2), and 112 μg per milliliter (cohort 3) at steady state. Since the factor for the conversion of micrograms of emicizumab per milliliter to international units of equivalent factor VIII hemostatic activity per deciliter was estimated to be approximately 0.3, on the basis of nonclinical data (see the Description section in the Supplementary Appendix), these trough levels were expected to correspond to 3, 10, and 30 IU of equivalent factor VIII activity per deciliter, respectively, and to be sufficient to prevent bleeding. We evaluated outcome measures up to week 12 (or at the time of treatment discontinuation if the regimen was stopped early) before enrolling patients at the next dose level. Bleeding episodes were treated with factor VIII or a bypassing agent, according to standard clinical practice.
Outcome Measures
Emicizumab plasma concentrations, activated partial-thromboplastin time, thrombin generation triggered by activated factor XI (factor XIa), factor IX and factor X plasma concentrations, and plasma anti-emicizumab antibodies were assessed as previously described. 23 Safety outcomes included adverse events, laboratory test results, vital signs, and 12-lead electrocardiograms. The annualized bleeding rate, an exploratory efficacy end point, was calculated as 365.25 times the number of bleeding episodes, divided by the number of days in the treatment period. A bleeding episode was defined as bleeding or suspected bleeding that required treatment with clotting factors. The overall annualized bleeding rate and the annualized bleeding rates at joints and at target joints (i.e., joints at which ≥3 spontaneous bleeding episodes had occurred during the 6 months 26 before study entry) during emicizumab treatment were compared with the annualized bleeding rates for the 6 months before study entry (calculated retrospectively from medical records).
Statistical Analysis
Summary statistics were calculated for demographic characteristics and pharmacokinetic, pharmacodynamic, and safety outcomes. The target sample size was not based on hypothesis testing; we planned to enroll at least six patients per cohort to enable exploratory evaluations. Bleeding episodes during the 6 months before study entry and between the first dose and week 12 (or treatment discontinuation) were summarized. Given the small size of the cohorts, statistical comparisons were not performed. 
R esult s
Study Population
A total of 18 Japanese patients with severe hemophilia A participated in the study, with 6 patients in each cohort. The patients' ages and weights were similar across the cohorts (Table 1, and  Table S1 in the Supplementary Appendix). Each cohort included 1 or 2 adolescent patients (age range, 12 to 18 years) and 3 or 4 patients with factor VIII inhibitors. All patients without factor VIII inhibitors had received secondary prophylaxis (defined as prophylaxis started after the onset of joint damage or other clinically significant bleeding 27 ). Over the 6-month period before study entry, the annualized bleeding rate was highest in cohort 1. Six patients each in cohorts 1 and 2, and 3 patients in cohort 3, had target joints at baseline. All patients completed 12 weeks of emicizumab administration except for 1 patient in cohort 2, who discontinued treatment on day 29 because of injection-site erythema. * Plus-minus values are means ±SD. HIV denotes human immunodeficiency virus. † All patients without factor VIII inhibitors had received secondary prophylaxis (defined as prophylaxis started after the onset of joint damage or other clinically significant bleeding 27 ). ‡ The annualized bleeding rate for each patient was calculated as 365.25 times the number of bleeding episodes that required treatment with coagulation-factor products, divided by the number of days in the 6-month period before study enrollment. § Target joints were defined as joints at which three or more episodes of spontaneous bleeding had occurred during the 6-month period before enrollment. 
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Pharmacokinetic and Pharmacodynamic Outcomes
Plasma emicizumab concentrations had a dosedependent increase, as predicted on the basis of nonclinical pharmacokinetic data. In cohorts 1 and 2, mean (±SD) trough levels reached steady state by week 12 (10.3±4.54 and 29.9±6.88 μg per milliliter, respectively) (Fig. 1A) . In cohort 3, in which the initial dose and subsequent doses were the same, the mean trough level gradually increased to 87.9±20.0 μg per milliliter by week 12 but did not reach steady state. During treatment, the activated partial-thromboplastin time remained short, and factor XIa-triggered thrombin generation was detected at each assessment in all three cohorts (Fig. 1B and 1C, respectively) .
Efficacy Outcomes
During prophylactic treatment with emicizumab, the bleeding rate was reduced markedly from the rate at baseline in all cohorts. Median annualized bleeding rates decreased from 32. . The annualized bleeding rate decreased among 17 patients regardless of the presence or absence of factor VIII inhibitors and prior prophylaxis; 1 patient without factor VIII inhibitors (in cohort 3) had an annualized bleeding rate of 0.0 both at baseline and while receiving emicizumab (Fig. 2) . Eight of 11 patients with factor VIII inhibitors (73%) and 5 of 7 patients without factor VIII inhibitors (71%) had no bleeding episodes. All 21 bleeding episodes were successfully treated with a clotting factor (factor VIII or a bypassing agent), and 18 of the episodes (86%) resolved with one or two doses (Table S2 in the Supplementary Appendix). Episodic use of clotting factors to control bleeding was reduced from baseline (Table S3 in the Supplementary Appendix).
One patient without factor VIII inhibitors (in cohort 1) had an unusually large number of bleeding episodes, even with factor VIII prophylaxis at a dose of 2000 IU three times per week before the study treatment began. During emicizumab treatment, this patient had 14 nontraumatic bleeding episodes (i.e., episodes not caused by any evident external triggers) at joints, with 13 of the episodes at target joints. These results were attributed to very high levels of physical activity and hemophilic arthropathy. Nevertheless, 11 of 14 episodes resolved with one or two doses of factor VIII.
Safety Outcomes
Weekly administration of emicizumab had an acceptable safety profile over the 12-week treatment period. A total of 43 adverse events were observed in 15 of the 18 patients (83%) ( Table 2) , no serious adverse events were reported, and the number of patients with at least 1 adverse event was similar across the cohorts. All adverse events were mild, except for 2 moderate events (upper respiratory tract infection in a patient in cohort 2 and headache in a patient in cohort 3). Nasopharyngitis was the only adverse event reported in 15% or more of the patients (Table 2 ). Adverse events thought by the investigators to be possibly related to emicizumab included malaise, injection-site erythema, injection-site rash, injection-site pruritus, injection-site discomfort, diarrhea, increased C-reactive protein level, and increased blood creatine kinase level. Injection-site erythema, reported twice in 1 patient (cohort 2), resulted in treatment discontinuation on day 29; the events were mild and resolved.
No evidence of clinically relevant coagulation abnormalities was noted on the basis of reported adverse events (Table 2) . No thromboembolic events were reported, even when factor VIII or a bypassing agent was administered as episodic therapy in the presence of emicizumab. Laboratory test results are shown in Figure S3 in the Supplementary Appendix. Emicizumab did not affect factor IX or factor X plasma concentrations (Fig. 3) . Anti-emicizumab antibodies did not develop during treatment in any of the patients. One patient had a positive test for antiemicizumab antibodies at baseline and had a transient increase in the C-reactive protein level on day 3, which did not affect the pharmacokinetics or pharmacodynamics of emicizumab during treatment (data not shown). 
Discussion
Prophylactic treatment with weekly subcutaneous administration of emicizumab reduced the bleeding rate in patients with severe hemophilia A, irrespective of the presence or absence of factor VIII inhibitors. Thirteen of the 18 patients (72%) had no bleeding episodes and did not require clotting factors, including 3 patients with factor VIII inhibitors who had had frequent bleeding episodes, even during prophylaxis with bypassing agents, before receiving emicizumab treatment (Fig. 2) . This finding suggests that emicizumab has the potential to maintain high hemostatic activity in patients with hemophilia A. Plasma emicizumab trough levels at week 12 were approximately 10, 30, and 90 μg per milliliter in cohorts 1, 2, and 3, respectively. On the basis of nonclinical in vivo data (see the Description section in the Supplementary Appendix), these levels were expected to result in equivalent hemostatic activity of approximately 3, 9, and 27 IU of factor VIII per deciliter in cohorts 1, 2, and 3, respectively. As reported in a previous study, 12 the relationship between the annualized bleeding rate at joints and the estimated equivalent factor VIII activity in our study was asymptotic (the median annualized bleeding rate at joints was 0.0 at higher doses [i.e., in cohorts 2 and 3]). The plasma emicizumab concentrations achieved in these cohorts were expected to correspond to Data below the limits of quantification (<0.05 μg per milliliter for the plasma emicizumab concentration and <2 nmol per liter for peak height for thrombin generation) were not included in the analyses. Summary statistics were not calculated when measured values were out of the quantification range in the majority of patients for each cohort and time point. The reference ranges for APTT and peak height for thrombin generation are 25.4 to 37.2 seconds and 341 to 489 nmol per liter, respectively, which were derived from the mean baseline values ±1.96 SD for 40 healthy Japanese participants enrolled in the first-in-human study of emicizumab.
at least 10 IU of factor VIII activity per deciliter. The results in cohort 2 suggest that the factor would be 0.3 or higher for the conversion of micrograms of emicizumab per milliliter to international units of equivalent factor VIII hemostatic activity per deciliter and that treatment with emicizumab may convert severe hemophilia A to a moderate phenotype (factor VIII activity, 1 to 5 IU per deciliter) or even a mild phenotype (>5 to <40 IU per deciliter). We hypothesize that 30 to 50 μg of emicizumab per milliliter would correspond to at least 10 to 15 IU of equivalent factor VIII activity per deciliter, which is a level of activity associated with a very low risk of joint bleeding. 12 Since the steady-state trough level in cohort 2 was approximately 30 μg per milliliter, doses slightly higher than 1 mg per kilogram once weekly may be needed to meet desired factor VIII-equivalent activity levels. In this study, pharmacodynamic markers of the activated partial-thromboplastin time and factor XIa-triggered thrombin generation did not clearly discriminate between cohorts 2 and 3 (Figs. S4 and S5 in the Supplementary Appendix). Further investigations are needed to establish more appropriate pharmacodynamic markers. For example, thrombin generation triggered by a low level of tissue factor showed a clear concentration-dependent response when emicizumab (30 to 300 μg per milliliter) was added in vitro to factor VIII-deficient plasma (Fig. S6 in the Supplementary Appendix). 28 Neither serious nor thrombotic adverse events occurred during the study (Table 2) . Although adverse events thought to be related to the study treatment occurred more frequently in cohort 3 than in the other cohorts, we could not draw any conclusions about a dose-dependent relationship between emicizumab and adverse events because of the small sample and the low incidence of treatment-related adverse events in each cohort. In addition, although some patients had transient changes in laboratory values, including d-dimer and thrombin-antithrombin complex, no emicizumab-dependent change over time toward hypercoagulation was evident. Treatment of bleeding episodes with factor VIII or bypassing agents was successful, suggesting that emicizumab is unlikely to disturb the functions of clotting factor agents. Furthermore, we did not observe emicizumab-dependent accumulation or depletion of factor IX or factor X, probably because of the very weak antigen-binding affinity of emicizumab to each factor. 28 Anti-emicizumab antibodies did not develop in any of the patients during the study. This finding is consistent with the expectation that the immunogenicity of emicizumab, which was reduced on the basis of in silico analyses, 21 is low and similar to or less than the immunogenicity of other humanized antibodies that have been approved by the Food and Drug Administration. 29 The limitations of this study included its nonrandomized, open-label design, the lack of a contemporaneous control group, the small number of patients, and the short period of observation, which could contribute to bias. In addition, the imbalance in baseline severity of hemophilia A among the cohorts limits the ability to evaluate the relationship between the dose of emicizumab and the treatment response. During 12 weeks of treatment, the pharmacokinetics in cohort 3 did not reach steady state. An extension study is currently under way to examine the long-term safety and efficacy of emicizumab (JapicCTI number, 132195).
In conclusion, this study showed that onceweekly subcutaneous administration of emicizumab as prophylaxis is safe and has the potential to reduce or prevent bleeding episodes in patients who have severe hemophilia A with or without factor VIII inhibitors. 
